Business Context and Reporting Period
This Form 8-K Current Report from SBC Medical Group Holdings Inc covers events occurring on July 8, 2026, specifically the Company's 2026 Annual Meeting of Stockholders. The filing addresses corporate governance changes, including a notice of non-compliance with Nasdaq listing rules regarding board independence and the approval of amendments to the Company's Charter and Bylaws.
Key Financial Metrics
The filing text does not provide specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting outcomes.
Material Changes and Governance Events
Nasdaq Listing Compliance (Item 3.01)
- Non-Compliance Notice: On July 8, 2026, the Company notified Nasdaq that it ceased compliance with independence rules for the Board of Directors and Audit Committee following the departure of director Mike Sayama.
- Current Status: The Board currently consists of four members (two independent) and the Audit Committee has two independent directors, falling short of Nasdaq requirements for a majority independent Board and a three-member independent Audit Committee.
- Cure Period: Nasdaq granted a cure period until the earlier of the next annual shareholders' meeting or July 9, 2027 (or January 5, 2027, if the next meeting is held before that date).
- Remediation Plan: The Board is searching for a fifth independent director to restore compliance.
Charter and Bylaw Amendments (Item 5.03)
- Restated Charter: Stockholders approved amendments effective July 9, 2026, including:
- Elimination of plurality voting for director elections.
- Removal of the "for cause" requirement for director removal.
- Opt-out of Section 203 of the Delaware General Corporation Law (DGCL).
- Exculpation of officers.
- Amended Bylaws: Adopted on July 8, 2026, to update quorum requirements, incorporate universal proxy rules, and require director nominees failing to receive a majority of votes in uncontested elections to tender their resignation.
Shareholder Voting Results (Item 5.07)
Of 102,576,943 shares outstanding, 93,987,291 shares were represented at the Annual Meeting, constituting a quorum.
| Proposal | Result | Key Vote Counts (For / Against) |
|---|---|---|
| Election of Directors (4 nominees) | Approved | ~90.4M For / ~1.1M-1.6M Withheld |
| Ratification of Auditor (MaloneBailey, LLP) | Approved | 93,954,650 For / 20,612 Against |
| Amend Charter: Eliminate Plurality Voting | Approved | 90,553,173 For / 997,140 Against |
| Amend Charter: Remove "For Cause" Removal | Approved | 90,554,214 For / 996,594 Against |
| Amend Charter: Opt Out of DGCL Section 203 | Approved | 90,540,413 For / 1,010,340 Against |
| Amend Charter: Officer Exculpation | Approved | 90,016,235 For / 1,534,035 Against |
| Amend Charter: Technical Changes | Approved | 90,571,117 For / 979,599 Against |
Outlook, Risks, and Contingencies
- Listing Risk: While the Company's listing is not immediately affected, failure to appoint a new independent director within the cure period could result in delisting.
- Forward-Looking Statements: The Company cautions that statements regarding the board composition and compliance efforts are subject to risks and uncertainties, including regulatory changes and market conditions.
Investor Verification Checklist
- Verify the timeline for the appointment of the new independent director to ensure compliance with the July 9, 2027 deadline.
- Review the full text of the Restated Charter (Exhibit 3.1) and Amended Bylaws (Exhibit 3.2) to understand the specific implications of the new voting and removal standards.
- Monitor future filings for updates on the search for the fifth board member.
- Confirm the impact of the DGCL Section 203 opt-out on potential takeover defenses.